PRIORITY: Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice

Sponsor
Maxima Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT06103916
Collaborator
Radboud University Medical Center (Other), The Netherlands Cancer Institute (Other), Catharina Ziekenhuis Eindhoven (Other), ZonMw: The Netherlands Organisation for Health Research and Development (Other)
613
1
69.6
8.8

Study Details

Study Description

Brief Summary

Multicenter prospective cohort study in which patients ≥18 years with an ovarian tumor for which an ultrasound has been performed in accordance with IOTA criteria and the IOTA ADNEX model has been applied are included. Ultrasound data from these patients will be prospectively recorded in a database to determine the diagnostic accuracy of the IOTA ADNEX model in Dutch gynaecological practice.

Condition or Disease Intervention/Treatment Phase
  • Other: Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.

Detailed Description

Rationale: Correct pre-operative classification of ovarian tumors is critical for optimal treatment of both women with benign and malignant ovarian tumors. The International Ovarian Tumor Analysis (IOTA) consortium developed several risk-assessment strategies, including the Assessment of Different NEoplasias in the adneXa (ADNEX) model. This is a polytomous model that estimates the risk of malignancy in women with an ovarian tumor and can help differentiate benign from malignant ovarian tumors. Recent validation studies have shown superior diagnostic accuracy of the ADNEX model compared with previously developed risk-assessment strategies. However, the diagnostic accuracy of this model in daily clinical practice is still unknown. Furthermore, expertise is necessary to use this model before the results are reliable. With the recently published Dutch guideline on risk-assessment strategies of ovarian tumors, in which it is advised to use the ADNEX model, clinical data on diagnostic performance of the ADNEX model in daily Dutch gynaecological practice are necessary. Lower sensitivity and/or specificity of the model will have significant influence on the referral practice in The Netherlands.

Objective: To determine the diagnostic accuracy of the IOTA ADNEX model in the discrimination between benign and malignant ovarian tumors in daily gynaecological practice in The Netherlands.

Study design: Multicentre prospective cohort study. Hospitals from three oncologic networks in the Netherlands will participate in this trial. Ultrasound data will be prospectively recorded in a database for a duration of five years by means of an electronic case report form (eCRF). With these data, the diagnostic accuracy of the IOTA ADNEX model will be calculated.

Study population: All women ≥ 18 years with an ovarian tumor for which ultrasound assessment in accordance with the IOTA definitions has been performed and the ADNEX model has been applied. Women with a tumor that meets the IOTA criteria of a benign 'easy descriptor' will be excluded.

Data collection: All patients eligible for this study will be asked for informed consent and clinical data will be collected through eCRFs. Data will be collected in a cloud-based database by the treating physician.

Main study parameters/endpoints: The sensitivity, specificity and area under the curve of the IOTA ADNEX model.

Secondary analysis: Secondary endpoints include the influence of practice variation (eg type of center, volume per center, prevalence of malignancy, availability of consultation time specifically aimed at performing ultrasounds according to IOTA criteria) and the experience of the ultrasound performer on the diagnostic accuracy of the IOTA ADNEX model.

Study Design

Study Type:
Observational
Anticipated Enrollment :
613 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice
Actual Study Start Date :
Jul 15, 2022
Anticipated Primary Completion Date :
Aug 1, 2027
Anticipated Study Completion Date :
May 1, 2028

Outcome Measures

Primary Outcome Measures

  1. Diagnostic accuracy of the IOTA ADNEX model [5 years (2022 - 2027)]

    Area under the curve (AUC)

  2. Sensitivity and specificity [5 years (2022 - 2027)]

    Sensitivity and specificity of the IOTA ADNEX model (%) at different thresholds

Secondary Outcome Measures

  1. Factors influencing the diagnostic performance of the IOTA ADNEX model [5 years (2022 - 2027)]

    Influence on the diagnostic performance of the type of center, volume per center, prevalence of malignancy, experience of ultrasound performer, availability of consultation time specifically aimed at performing ultrasounds according to IOTA criteria

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Age ≥ 18 years

  2. Presence of a complex ovarian tumor

  3. Ultrasound assessment in accordance with IOTA definitions and application of the ADNEX model

  4. Understanding of Dutch language

Exclusion Criteria:
  1. Women with an ovarian tumor that meets the IOTA criteria of a benign easy descriptor:

  2. Unilocular tumor with ground glass echogenicity in premenopausal woman suggestive of endometrioma

  3. Unilocular tumor with mixed echogenicity and acoustic shadows in premenopausal women (suggestive of benign cystic teratoma)

  4. Unilocular tumor with regular walls and maximal diameter < 10cm (suggestive of simple cyst or cystadenoma)

  5. Remaining unilocular tumors with regular walls

  6. Histologically proven malignancy prior to ultrasound

Contacts and Locations

Locations

Site City State Country Postal Code
1 Máxima Medical Centre Veldhoven Noord-Brabant Netherlands 5504 DB

Sponsors and Collaborators

  • Maxima Medical Center
  • Radboud University Medical Center
  • The Netherlands Cancer Institute
  • Catharina Ziekenhuis Eindhoven
  • ZonMw: The Netherlands Organisation for Health Research and Development

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Esther Lems, Medical doctor, Principal Investigator, Maxima Medical Center
ClinicalTrials.gov Identifier:
NCT06103916
Other Study ID Numbers:
  • N21.105
First Posted:
Oct 27, 2023
Last Update Posted:
Oct 27, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Esther Lems, Medical doctor, Principal Investigator, Maxima Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 27, 2023